Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM) Stock Price, News & Analysis

Company Overview

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Key Stats

• Today's Range: C$0.29 to C$0.29
• 50-Day Range: C$0.29 to C$0.29
• 52-Week Range: C$0.29 to C$1.50
• Volume: 4,800 shs
• Average Volume: 2,858 shs
• Market Capitalization: C$36.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZOM Stock Analysis - Frequently Asked Questions

How have ZOM shares performed this year?

Zomedica Pharmaceuticals Corp. (ZOM.V)'s stock was trading at C$0.29 at the beginning of the year. Since then, ZOM stock has increased by 0.0% and is now trading at C$0.29.
View the best growth stocks for 2025 here.

How do I buy shares of Zomedica Pharmaceuticals Corp. (ZOM.V)?

Shares of ZOM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Zomedica Pharmaceuticals Corp. (ZOM.V) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica Pharmaceuticals Corp. (ZOM.V) investors own include Ocugen (OCGN), T2 Biosystems (TTOO), Meta Platforms (META), Bionano Genomics (BNGO), Onconova Therapeutics (ONTX), Biocept (BIOC) and Ford Motor (F).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: CVE:ZOM
• CUSIP: N/A
• CIK: N/A
• Web: www.zomedica.com
• Phone: 734-369-2555
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 4.91
• Current Ratio: 15.31
• Quick Ratio: 15.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.05 per share
• Price / Cash Flow: 5.38
• Book Value: C$0.05 per share
• Price / Book: 5.82

Miscellaneous

• Outstanding Shares: 128,872,000
• Free Float: N/A
• Market Cap: C$36.73 million
• Optionable: Not Optionable
• Beta: N/A